New Prostate Publication from Project 2 Co-I Dr. Douglas Strand

A new study in Prostate from UW O’Brien Center Project 2 Co-I Dr. Douglas Strand (Associate Professor of Urology, UT Southwestern), and colleagues at UT Southwestern Medical Center evaluates the histological features of benign prostatic hyperplasia (BPH) surgical specimens in patients that were 5-alpha reductase inhibitor (5ARI)-treated or untreated to develop a model of prostate cellular composition based on prostate specific antigen (PSA) density. They determined that PSA density could provide a decisive variable for estimating BPH cellular content and may eventually improve selection of patients for 5ARI treatment. Read more here: https://pubmed.ncbi.nlm.nih.gov/35652548/.